Insider · CIK 0001764157

Barrett Elizabeth A.

Reports to the SEC for 4 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001764157

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	ALLOAllogene Therapeutics, Inc. · Restricted Stock UnitA Award	Director	AAward	+95.4K sh	—	—	95,400
2026-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsA Award	Chief Executive Officer	AAward	+153K sh	—	—	153,195
2025-07-31	Sage Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−3,000 sh	—	—	0
2025-07-31	Sage Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.5K sh	—	—	0
2025-07-28	URGNUroGen Pharma Ltd. · Performance Stock UnitsA Award	Chief Executive Officer	AAward	+87.6K sh	—	—	87,615
2025-06-18	ALLOAllogene Therapeutics, Inc. · Restricted Stock UnitA Award	Director	AAward	+95.4K sh	—	—	95,400
2025-06-11	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+21.5K sh	—	—	21,500
2025-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsA Award	Chief Executive Officer	AAward	+96.4K sh	—	—	96,377
2024-06-05	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+191K sh	—	—	191,082
2024-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsA Award	Chief Executive Officer	AAward	+87.6K sh	—	—	87,615
2023-06-13	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+116K sh	—	—	116,120
2023-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsA Award	Chief Executive Officer	AAward	+75K sh	—	—	75,000
2023-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−13.3K sh	—	—	13,334
2023-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−5,000 sh	—	—	0
2023-01-31	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+13.3K sh	—	—	326,691
2023-01-31	URGNUroGen Pharma Ltd. · Performance Stock UnitsA Award	Chief Executive Officer	AAward	+100K sh	—	—	100,000
2023-01-31	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+5,000 sh	—	—	313,358
2023-01-31	URGNUroGen Pharma Ltd. · Employee Stock Option (right to buy)A Award	Chief Executive Officer	AAward	+125K sh	—	—	125,000
2022-06-15	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+71.1K sh	—	—	71,070
2022-01-31	URGNUroGen Pharma Ltd. · Stock Option (right to buy)A Award	Chief Executive Officer	AAward	+150K sh	—	—	150,000
2022-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−13.3K sh	—	—	26,667
2022-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−5,000 sh	—	—	5,000
2022-01-31	URGNUroGen Pharma Ltd.S Sale	Chief Executive Officer	SSale	−5,960 sh	$7.58	−$45.2K	308,358
2022-01-31	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+13.3K sh	—	—	314,318
2022-01-31	URGNUroGen Pharma Ltd.S Sale	Chief Executive Officer	SSale	−2,235 sh	$7.58	−$16.9K	300,985
2022-01-31	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+5,000 sh	—	—	303,220
2022-01-04	URGNUroGen Pharma Ltd.S Sale	Chief Executive Officer	SSale	−47K sh	$9.15	−$430K	298,220
2022-01-03	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−106K sh	—	—	0
2022-01-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+106K sh	—	—	345,188
2021-07-30	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+63.4K sh	—	—	63,385
2021-05-19	URGNUroGen Pharma Ltd.F Tax Payment	Chief Executive Officer	FTax Payment	−1,240 sh	$17.51	−$21.7K	239,499
2021-05-19	URGNUroGen Pharma Ltd.F Tax Payment	Chief Executive Officer	FTax Payment	−2,185 sh	$17.51	−$38.3K	240,739
2021-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsA Award	Chief Executive Officer	AAward	+40K sh	—	—	40,000
2021-01-31	URGNUroGen Pharma Ltd. · Stock Option (right to buy)A Award	Chief Executive Officer	AAward	+150K sh	—	—	150,000
2021-01-31	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+5,000 sh	—	—	242,924
2021-01-31	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−5,000 sh	—	—	10,000
2021-01-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+8,807 sh	—	—	237,924
2021-01-03	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−8,807 sh	—	—	105,689
2020-12-14	URGNUroGen Pharma Ltd.P Purchase	Chief Executive Officer	PPurchase	+10K sh	$18.50	+$185K	229,117
2020-12-04	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+61.7K sh	—	—	219,117
2020-12-04	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−61.7K sh	—	—	114,496
2020-12-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+8,808 sh	—	—	219,117
2020-12-03	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−8,808 sh	—	—	114,496
2020-11-03	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−8,808 sh	—	—	123,304
2020-11-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+8,808 sh	—	—	210,309
2020-10-03	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−8,808 sh	—	—	132,112
2020-10-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+8,808 sh	—	—	201,501
2020-09-03	URGNUroGen Pharma Ltd. · Restricted Stock UnitsM Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	−8,807 sh	—	—	140,920
2020-09-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+8,807 sh	—	—	192,693
2020-08-03	URGNUroGen Pharma Ltd.M Exercise/Conversion	Chief Executive Officer	MExercise/Conversion	+8,807 sh	—	—	183,886

Recent filings

Accepted (ET)
Jun 234
Barrett Elizabeth A.0001764157-26-000004
SEC(opens sec.gov)
Feb 194
Barrett Elizabeth A.0001437749-26-004638
SEC(opens sec.gov)
Jul 314
Barrett Elizabeth A.0000950170-25-100675
SEC(opens sec.gov)
Jul 304
Barrett Elizabeth A.0001437749-25-023969
SEC(opens sec.gov)
Jun 234
Barrett Elizabeth A.0001737287-25-000074
SEC(opens sec.gov)
Jun 134
Barrett Elizabeth A.0001562180-25-004787
SEC(opens sec.gov)
Feb 44
Barrett Elizabeth A.0001437749-25-002683
SEC(opens sec.gov)
Jun 74
Barrett Elizabeth A.0001593968-24-000840
SEC(opens sec.gov)
Feb 24
Barrett Elizabeth A.0001437749-24-003012
SEC(opens sec.gov)
Jun 154
Barrett Elizabeth A.0001593968-23-001012
SEC(opens sec.gov)
Feb 24
Barrett Elizabeth A.0001437749-23-002358
SEC(opens sec.gov)
Jun 174
Barrett Elizabeth A.0001214659-22-008168
SEC(opens sec.gov)
Feb 24
Barrett Elizabeth A.0001209191-22-006383
SEC(opens sec.gov)

Companies

Address

210 EAST GRAND AVENUE

SOUTH SAN FRANCISCO, CA, 94080